Clinical Trials on Allergy to Fenugreek in South Africa

Total 223 results

Amgen

Completed

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

Dyslipidemia | Medical Conditions to be Studied | ASCVD Management

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Aeglea Biotherapeutics

Terminated

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Homocystinuria Due to Cystathionine Beta-Synthase Deficiency

United States, United Kingdom, Australia
GlaxoSmithKline

Completed

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Rhinitis, Allergic, Perennial

United States, Argentina, Canada, France, Peru, Italy, Chile
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
AbbVie (prior sponsor, Abbott)

Completed

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (LOTOS)

Moderate to Severe Plaque Psoriasis

Germany
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Rhinitis, Allergic, Perennial

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201

Neurotoxicity | Long-term Effects Secondary to Cancer Therapy in Children

United States, Canada
Indivior Inc.

Active, not recruiting

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Moderate to Severe Opioid-use Disorder

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Allergic Rhinitis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
GlaxoSmithKline

Completed

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

Estonia, United States, Canada, Germany, Slovakia, Russian Federation, Hungary
UCB Pharma

Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months (BALL)

Allergic Rhinitis | Chronic Urticaria

United States
Pulmatrix Inc.

Terminated

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis

United States, Australia, United Kingdom, India, Poland
Egalet Ltd

Completed

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Moderate-to-severe Chronic Low Back Pain

United States
GlaxoSmithKline

Completed

Study Of Patients With Allergic Rhinitis And Asthma

Asthma

United States
Gilead Sciences

Terminated

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH)

Liver Fibrosis Due to NASH

United States, Canada, France, Italy, Germany, Puerto Rico, Spain, United Kingdom
GlaxoSmithKline

Completed

Perennial Allergic Rhinitis Study In Pediatric Subjects

Rhinitis, Allergic, Perennial

United States, Argentina, Slovakia, Finland, Chile, Mexico, Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Genentech, Inc.

Completed

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy (XPORT)

Allergic Asthma

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
GlaxoSmithKline

Completed

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Asthma

United States, Estonia, Canada, Poland
Pulmatrix Inc.

Terminated

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

ABPA

Australia, United States, United Kingdom, France
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

Allergic Fungal Rhinosinusitis

China, Argentina, Israel, United States, Canada, India, Japan, Saudi Arabia, Turkey
UCB Pharma

Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin (PAL)

Allergic Rhinitis | Chronic Urticaria

United States
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, South Africa, Germany, Netherlands
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

Choroidal Neovascularization Secondary to Pathologic Myopia

Korea, Republic of, China, Australia, Singapore, Poland, France, Germany, Italy, Taiwan, Hong Kong, Spain
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Australian and New Zealand Intensive Care Research...
The Alfred

Not yet recruiting

Trial of ECMO to De-Sedate, Extubate Early and Mobilise in Hypoxic Respiratory Failure (REDEEM)

Pneumonia | Extracorporeal Membrane Oxygenation | Mechanical Ventilation Complication | Hypoxemia | COVID-19 Respiratory Infection | Acute Respiratory Distress Syndrome Due to COVID-19

Australia, Germany
Galderma R&D

Completed

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Canada, Czechia, Germany, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain, United Kingdom
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Moderate to Severe Asthma

Korea, Republic of, United States, Spain, Poland, Japan, Canada, Germany, Belgium, Argentina
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

Moderate-to-Severe Atopic Dermatitis | Atopic Eczema

United States
Takeda

Terminated

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Australia, United Kingdom, Switzerland
The University of Queensland
University of Copenhagen; Erasmus Medical Center; Monash University; Hôpital Cochin and other collaborators

Recruiting

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)

Pulmonary Disease Due to Mycobacteria (Diagnosis)

Australia, Canada, Denmark, France, Ireland, Netherlands, New Zealand, United Kingdom, Singapore
AnGes USA, Inc.

Recruiting

Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

Peripheral Artery Disease | Chronic Limb Threatening Ischemia | Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease | Ischemic Ulcer of Foot

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Head and Neck Cancer | Skin Reactions Secondary to Radiation Therapy

United States, Canada
Nektar Therapeutics

Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Moderate to Severe Atopic Dermatitis

Spain, Czechia, United States, Australia, Croatia, Bulgaria, Poland, Canada, Germany, Hungary
Gilead Sciences

Terminated

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Liver Fibrosis Due to NASH

United States, Spain, France, Canada, Germany, Italy, Puerto Rico, United Kingdom, Belgium
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
Regeneron Pharmaceuticals
Bayer

Completed

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Macular Edema Secondary to Central Retinal Vein Occlusion

United States, Canada, Colombia, Israel, India
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Obesity | Genetic Obesity | Obesity Due to Melanocortin 4 Receptor Deficiency

United States, United Kingdom, Germany, Netherlands, France, Canada, Greece, Israel, Spain
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden

Clinical Trials on Allergy to Fenugreek in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations